NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Crinetics Pharmaceuticals, Inc. Logo
Develops oral therapeutics for endocrine diseases and endocrine-related tumors.
United States of America
CRNX
Develops drug delivery technology for localized chemotherapy in solid tumors.
Virgin Islands (British)
CRTX
CRISPR Therapeutics AG Logo
A gene-editing company developing gene-based medicines for serious diseases.
United States of America
CRSP
Crossject Logo
Develops emergency medications delivered via a needle-free auto-injector platform.
France
ALCJ
CSL Ltd. Logo
Global biotechnology company developing biotherapies, vaccines, and specialty medicines.
Australia
CSL
CS Medica A/S Logo
Develops and manufactures OTC medical devices and cosmetics containing cannabidiol.
Denmark
CSMED
CTC BIO, INC. Logo
Develops and manufactures human and animal health products using microbial fermentation.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops biologics to selectively modulate the immune system for cancer and autoimmune diseases.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires, develops, and commercializes branded drugs for hospital and acute care.
United States of America
CPIX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.